Treatment Strategies in Relapsed Refractory Multiple Myeloma

Opinion
Video

Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.

CN24_FO_MM_Seg01_Strategies
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC
      Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC
      Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS
      Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS
      Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
      Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
      Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02
      Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02
      Deciding Which RP to Utilize
      Deciding Which RP to Utilize
      Making Sense of PARP Inhibitors
      Making Sense of PARP Inhibitors
      Consideration for Other Androgen Receptor Inhibitors
      Consideration for Other Androgen Receptor Inhibitors
      Prostate Cancer in 2025
      Prostate Cancer in 2025
      Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
      Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
      5 experts in this video
      Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
      Related Content
      Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

      Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma

      Roman Fabbricatore
      March 25th 2025
      Article

      Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

      Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma

      Roman Fabbricatore
      March 21st 2025
      Article

      Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Tim Cortese
      March 14th 2025
      Article

      Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      ONCOLOGY Staff
      March 9th 2025
      Article

      A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.